Have any questions? 706-721-6582 or cts@augusta.edu
- Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1 (T-St1M)
Clinical Trial
Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1 (T-St1M)
People with type 1 diabetes are 2-4 times more likely to die from heart disease than people without diabetes. We know that both the small blood vessels and our skeletal muscles play important roles in heart health. We also know that the small blood vessels and skeletal muscles in type 1 diabetes do not work in the way that they should, which can lead to higher risk of heart disease. We do not know what is causing this poor small blood vessel and skeletal muscle health in people with type 1 diabetes. The overall goal of this project is to find what is causing poor small blood vessel and skeletal muscle health in type 1 diabetes. People with diabetes have a lower level of Sirtuin-1, a protein that we think is adding to their poor blood vessel and muscle health. We are going to test if adding more of this protein in people with type 1 diabetes will help improve how their small blood vessels and skeletal muscles work. To do this, we will measure how the small blood vessels and skeletal muscles work in people with and without type 1 diabetes. We will then add more of the protein by giving them resveratrol or an inactive drug and repeat the tests to see which works better.
Eligibility Criteria
- Inclusion criteria: Adults (>18 years old) Men and premenopausal women All races Clinical diagnosis of insulin-dependent type 1 diabetes (patients only; controls will not have diabetes) Exclusion criteria: Clinical diagnosis of hepatic, cardiovascular, or renal disease Severely uncontrolled diabetes (HbA1C >12%) Diabetic complications (i.e. neuropathy) Uncontrolled hypertension (>140/90 mm Hg on therapy) Pregnancy Use of vasoactive medications